1
|
Nakata S, Murai J, Okada M, Takahashi H, Findlay TH, Malebranche K, Parthasarathy A, Miyashita S, Gabdulkhaev R, Benkimoun I, Druillennec S, Chabi S, Hawkins E, Miyahara H, Tateishi K, Yamashita S, Yamada S, Saito T, On J, Watanabe J, Tsukamoto Y, Yoshimura J, Oishi M, Nakano T, Imamura M, Imai C, Yamamoto T, Takeshima H, Sasaki AT, Rodriguez FJ, Nobusawa S, Varlet P, Pouponnot C, Osuka S, Pommier Y, Kakita A, Fujii Y, Raabe EH, Eberhart CG, Natsumeda M. Epigenetic upregulation of Schlafen11 renders
WNT- and SHH-activated medulloblastomas sensitive to cisplatin. Neuro Oncol 2023; 25:899-912. [PMID: 36273330 PMCID: PMC10158119 DOI: 10.1093/neuonc/noac243] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Intensive chemotherapeutic regimens with craniospinal irradiation have greatly improved survival in medulloblastoma patients. However, survival markedly differs among molecular subgroups and their biomarkers are unknown. Through unbiased screening, we found Schlafen family member 11 (SLFN11), which is known to improve response to DNA damaging agents in various cancers, to be one of the top prognostic markers in medulloblastomas. Hence, we explored the expression and functions of SLFN11 in medulloblastoma. METHODS SLFN11 expression for each subgroup was assessed by immunohistochemistry in 98 medulloblastoma patient samples and by analyzing transcriptomic databases. We genetically or epigenetically modulated SLFN11 expression in medulloblastoma cell lines and determined cytotoxic response to the DNA damaging agents cisplatin and topoisomerase I inhibitor SN-38 in vitro and in vivo. RESULTS High SLFN11 expressing cases exhibited significantly longer survival than low expressing cases. SLFN11 was highly expressed in the WNT-activated subgroup and in a proportion of the SHH-activated subgroup. While WNT activation was not a direct cause of the high expression of SLFN11, a specific hypomethylation locus on the SLFN11 promoter was significantly correlated with high SLFN11 expression. Overexpression or deletion of SLFN11 made medulloblastoma cells sensitive and resistant to cisplatin and SN-38, respectively. Pharmacological upregulation of SLFN11 by the brain-penetrant histone deacetylase-inhibitor RG2833 markedly increased sensitivity to cisplatin and SN-38 in SLFN11-negative medulloblastoma cells. Intracranial xenograft studies also showed marked sensitivity to cisplatin by SLFN11-overexpression in medulloblastoma cells. CONCLUSIONS High SLFN11 expression is one factor which renders favorable outcomes in WNT-activated and a subset of SHH-activated medulloblastoma possibly through enhancing response to cisplatin.
Collapse
Affiliation(s)
- Satoshi Nakata
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- Department of Neurosurgery, Gunma University, Maebashi, Japan
| | - Junko Murai
- Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan
| | - Masayasu Okada
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
| | - Haruhiko Takahashi
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
- Division of Neurosurgery, Department of Clinical Neuroscience, Faculty of Medicine University of Miyazaki, Miyazaki, Japan
| | - Tyler H Findlay
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Kristen Malebranche
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Akhila Parthasarathy
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Satoshi Miyashita
- Department of System Pathology for Neurological Disorders, Brain Research Institute, Niigata University, Niigata, Japan
| | - Ramil Gabdulkhaev
- Department of Pathology, Brain Research Institute Niigata University, Niigata, Japan
| | - Ilan Benkimoun
- Department of Neuropathology, GHU Paris-Psychiatrie Et Neurosciences, Sainte-Anne Hospital, Paris, France
| | - Sabine Druillennec
- Institut Curie, Centre de Recherche, F-91405, Orsay, France
- INSERM U1021, Centre Universitaire, F-91405, Orsay, France
- CNRS UMR 3347, Centre Universitaire, F-91405, Orsay, France
- Université Paris-Saclay, F-91405, Orsay, France
- Equipe Labellisée Ligue Nationale Contre le Cancer, F-91405, Orsay, France
| | - Sara Chabi
- Institut Curie, Centre de Recherche, F-91405, Orsay, France
- INSERM U1021, Centre Universitaire, F-91405, Orsay, France
- CNRS UMR 3347, Centre Universitaire, F-91405, Orsay, France
- Université Paris-Saclay, F-91405, Orsay, France
- Equipe Labellisée Ligue Nationale Contre le Cancer, F-91405, Orsay, France
| | - Eleanor Hawkins
- Institut Curie, Centre de Recherche, F-91405, Orsay, France
- INSERM U1021, Centre Universitaire, F-91405, Orsay, France
- CNRS UMR 3347, Centre Universitaire, F-91405, Orsay, France
- Université Paris-Saclay, F-91405, Orsay, France
- Equipe Labellisée Ligue Nationale Contre le Cancer, F-91405, Orsay, France
| | - Hiroaki Miyahara
- Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Japan
| | - Kensuke Tateishi
- Department of Neurosurgery, Yokohama City University, Yokohama, Japan
| | - Shinji Yamashita
- Division of Neurosurgery, Department of Clinical Neuroscience, Faculty of Medicine University of Miyazaki, Miyazaki, Japan
| | - Shiori Yamada
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
| | - Taiki Saito
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
| | - Jotaro On
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
| | - Jun Watanabe
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
| | - Yoshihiro Tsukamoto
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
| | - Junichi Yoshimura
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
| | - Makoto Oishi
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
| | - Toshimichi Nakano
- Department of Radiology and Radiation Oncology Niigata University Medical and Dental Hospital, Niigata, Japan
| | - Masaru Imamura
- Department of Pediatrics, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - Chihaya Imai
- Department of Pediatrics, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - Tetsuya Yamamoto
- Department of Neurosurgery, Yokohama City University, Yokohama, Japan
| | - Hideo Takeshima
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
- Division of Neurosurgery, Department of Clinical Neuroscience, Faculty of Medicine University of Miyazaki, Miyazaki, Japan
| | - Atsuo T Sasaki
- Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan
- Department of Internal Medicine, Department of Cancer Biology, University of Cincinnati College of Medicine, Columbus, Ohio, USA
| | - Fausto J Rodriguez
- Department of Neurosurgery, Brain Tumor Center at UC Gardner Neuroscience Institute, Cincinnati, Ohio, USA
| | | | - Pascale Varlet
- Department of Neuropathology, GHU Paris-Psychiatrie Et Neurosciences, Sainte-Anne Hospital, Paris, France
| | - Celio Pouponnot
- Institut Curie, Centre de Recherche, F-91405, Orsay, France
- INSERM U1021, Centre Universitaire, F-91405, Orsay, France
- CNRS UMR 3347, Centre Universitaire, F-91405, Orsay, France
- Université Paris-Saclay, F-91405, Orsay, France
- Equipe Labellisée Ligue Nationale Contre le Cancer, F-91405, Orsay, France
| | - Satoru Osuka
- Department of Neurosurgery, School of Medicine and O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Alabama, USA
| | - Yves Pommier
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
| | - Akiyoshi Kakita
- Department of Pathology, Brain Research Institute Niigata University, Niigata, Japan
| | - Yukihiko Fujii
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
| | - Eric H Raabe
- Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Charles G Eberhart
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Manabu Natsumeda
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan
| |
Collapse
|
2
|
Sarkar A, Liu NQ, Magallanes J, Tassey J, Lee S, Shkhyan R, Lee Y, Lu J, Ouyang Y, Tang H, Bian F, Tao L, Segil N, Ernst J, Lyons K, Horvath S, Evseenko D. STAT3 promotes a youthful epigenetic state in articular chondrocytes. Aging Cell 2023; 22:e13773. [PMID: 36638270 PMCID: PMC9924946 DOI: 10.1111/acel.13773] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 12/21/2022] [Indexed: 01/14/2023] Open
Abstract
Epigenetic mechanisms guiding articular cartilage regeneration and age-related disease such as osteoarthritis (OA) are poorly understood. STAT3 is a critical age-patterned transcription factor highly active in fetal and OA chondrocytes, but the context-specific role of STAT3 in regulating the epigenome of cartilage cells remain elusive. In this study, DNA methylation profiling was performed across human chondrocyte ontogeny to build an epigenetic clock and establish an association between CpG methylation and human chondrocyte age. Exposure of adult chondrocytes to a small molecule STAT3 agonist decreased DNA methylation, while genetic ablation of STAT3 in fetal chondrocytes induced global hypermethylation. CUT&RUN assay and subsequent transcriptional validation revealed DNA methyltransferase 3 beta (DNMT3B) as one of the putative STAT3 targets in chondrocyte development and OA. Functional assessment of human OA chondrocytes showed the acquisition of progenitor-like immature phenotype by a significant subset of cells. Finally, conditional deletion of Stat3 in cartilage cells increased DNMT3B expression in articular chondrocytes in the knee joint in vivo and resulted in a more prominent OA progression in a post-traumatic OA (PTOA) mouse model induced by destabilization of the medial meniscus (DMM). Taken together these data reveal a novel role for STAT3 in regulating DNA methylation in cartilage development and disease. Our findings also suggest that elevated levels of active STAT3 in OA chondrocytes may indicate an intrinsic attempt of the tissue to regenerate by promoting a progenitor-like phenotype. However, it is likely that chronic activation of this pathway, induced by IL-6 cytokines, is detrimental and leads to tissue degeneration.
Collapse
Affiliation(s)
- Arijita Sarkar
- Department of Orthopaedic Surgery, Keck School of Medicine of USCUniversity of Southern California (USC)Los AngelesCaliforniaUSA
| | - Nancy Q. Liu
- Department of Orthopaedic Surgery, Keck School of Medicine of USCUniversity of Southern California (USC)Los AngelesCaliforniaUSA
| | - Jenny Magallanes
- Department of Orthopaedic Surgery, Keck School of Medicine of USCUniversity of Southern California (USC)Los AngelesCaliforniaUSA
| | - Jade Tassey
- Department of Orthopaedic Surgery, Keck School of Medicine of USCUniversity of Southern California (USC)Los AngelesCaliforniaUSA
| | - Siyoung Lee
- Department of Orthopaedic Surgery, Keck School of Medicine of USCUniversity of Southern California (USC)Los AngelesCaliforniaUSA
| | - Ruzanna Shkhyan
- Department of Orthopaedic Surgery, Keck School of Medicine of USCUniversity of Southern California (USC)Los AngelesCaliforniaUSA
| | - Youngjoo Lee
- Department of Orthopaedic Surgery, Keck School of Medicine of USCUniversity of Southern California (USC)Los AngelesCaliforniaUSA
| | - Jinxiu Lu
- Department of Orthopaedic Surgery, Keck School of Medicine of USCUniversity of Southern California (USC)Los AngelesCaliforniaUSA
| | - Yuxin Ouyang
- Department of Orthopaedic Surgery, Keck School of Medicine of USCUniversity of Southern California (USC)Los AngelesCaliforniaUSA
| | - Hanhan Tang
- Department of Orthopaedic Surgery, Keck School of Medicine of USCUniversity of Southern California (USC)Los AngelesCaliforniaUSA
| | - Fangzhou Bian
- Department of Orthopaedic Surgery, Keck School of Medicine of USCUniversity of Southern California (USC)Los AngelesCaliforniaUSA
| | - Litao Tao
- Department of Biomedical SciencesCreighton UniversityNebraskaOmahaUSA
| | - Neil Segil
- Department of Stem Cell and Regenerative MedicineUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
- Eli and Edythe Broad CenterUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
| | - Jason Ernst
- Department of Biological ChemistryUniversity of CaliforniaLos AngelesCaliforniaUSA
- Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLALos AngelesCaliforniaUSA
- Computer Science DepartmentUniversity of CaliforniaLos AngelesCaliforniaUSA
- Jonsson Comprehensive Cancer Center, University of CaliforniaLos AngelesCaliforniaUSA
- Molecular Biology Institute, University of CaliforniaLos AngelesCaliforniaUSA
- Department of Computational MedicineUniversity of CaliforniaLos AngelesCaliforniaUSA
| | - Karen Lyons
- Department of Orthopaedic SurgeryUniversity of CaliforniaLos AngelesCaliforniaUSA
| | - Steve Horvath
- Department of Biostatistics, Fielding School of Public HealthUniversity of CaliforniaLos AngelesCaliforniaUSA
- Department of Human Genetics, David Geffen School of MedicineUniversity of CaliforniaLos AngelesCaliforniaUSA
| | - Denis Evseenko
- Department of Orthopaedic Surgery, Keck School of Medicine of USCUniversity of Southern California (USC)Los AngelesCaliforniaUSA
- Department of Stem Cell and Regenerative MedicineUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
- Eli and Edythe Broad CenterUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
| |
Collapse
|
4
|
Miyahara H, Natsumeda M, Kanemura Y, Yamasaki K, Riku Y, Akagi A, Oohashi W, Shofuda T, Yoshioka E, Sato Y, Taga T, Naruke Y, Ando R, Hasegawa D, Yoshida M, Sakaida T, Okada N, Watanabe H, Ozeki M, Arakawa Y, Yoshimura J, Fujii Y, Suenobu S, Ihara K, Hara J, Kakita A, Yoshida M, Iwasaki Y. Topoisomerase IIβ immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Children's Cancer Group. Brain Tumor Pathol 2021; 38:109-121. [PMID: 33704596 DOI: 10.1007/s10014-021-00396-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2020] [Accepted: 02/25/2021] [Indexed: 11/28/2022]
Abstract
We previously reported observing GLI3 in medulloblastomas expressing neuronal markers (NM) and/or glial fibrillary acidic protein (GFAP). Furthermore, patients with medulloblastomas expressing NM or GFAP tended to show favorable or poor prognosis, respectively. In the present study, we focused on the role of topoisomerase IIβ (TOP2β) as a possible regulator for neuronal differentiation in medulloblastomas and examined the pathological roles of GLI3, NM, GFAP, and TOP2β expressions in a larger population. We divided 124 medulloblastomas into three groups (NM-/GFAP-, NM +/GFAP-, and GFAP +) based on their immunoreactivity (IR) against NM and GFAP. The relationship among GLI3, NM, GFAP, and TOP2β was evaluated using fluorescent immunostaining and a publicly available single-cell RNA sequencing dataset. In total, 87, 30, and 7 medulloblastomas were classified as NM-/GFAP-, NM + /GFAP-, and GFAP +, and showed intermediate, good, and poor prognoses, respectively. GLI3-IR was frequently observed in NM +/GFAP- and GFAP + , and TOP2β-IR was frequently observed only in NM +/GFAP- medulloblastomas. In fluorescent immunostaining, TOP2β-IR was mostly co-localized with NeuN-IR but not with GFAP-IR. In single-cell RNA sequencing, TOP2β expression was elevated in CMAS/DCX-positive, but not in GFAP-positive, cells. NM-IR and GFAP-IR are important for estimating the prognosis of patients with medulloblastoma; hence they should be assessed in clinical practice.
Collapse
Affiliation(s)
- Hiroaki Miyahara
- Department of Neuropathology, Aichi Medical University, Institute for Medical Science of Aging, Aichi, Japan. .,Department of Pediatric Neuropathology, Aichi Medical University, Institute for Medical Science of Aging, Aichi, Japan.
| | - Manabu Natsumeda
- Department of Neurosurgery, University of Niigata, Brain Research Institute, Niigata, Japan
| | - Yonehiro Kanemura
- Department of Biomedical Research and Innovation, National Hospital Organization Osaka National Hospital, Institute for Clinical Research, Osaka, Japan
| | - Kai Yamasaki
- Department of Pediatric Hematology and Oncology, Osaka City General Hospital, Osaka, Japan
| | - Yuichi Riku
- Department of Neuropathology, Aichi Medical University, Institute for Medical Science of Aging, Aichi, Japan
| | - Akio Akagi
- Department of Neuropathology, Aichi Medical University, Institute for Medical Science of Aging, Aichi, Japan
| | - Wataru Oohashi
- Division of Biostatistics, Clinical Research Center, Aichi Medical University Hospital, Aichi, Japan
| | - Tomoko Shofuda
- Department of Biomedical Research and Innovation, National Hospital Organization Osaka National Hospital, Institute for Clinical Research, Osaka, Japan
| | - Ema Yoshioka
- Department of Biomedical Research and Innovation, National Hospital Organization Osaka National Hospital, Institute for Clinical Research, Osaka, Japan
| | - Yuya Sato
- Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan
| | - Takashi Taga
- Department of Pediatrics, Shiga University of Medical Science, Shiga, Japan
| | - Yuki Naruke
- Department of Pathology, Chiba Children's Hospital, Chiba, Japan
| | - Ryo Ando
- Department of Neurosurgery, Chiba Children's Hospital, Chiba, Japan
| | - Daiichiro Hasegawa
- Department of Hematology and Oncology, Children's Cancer Center, Kobe Children's Hospital, Hyogo, Japan
| | - Makiko Yoshida
- Department of Pathology, Children's Cancer Center, Kobe Children's Hospital, Hyogo, Japan
| | - Tsukasa Sakaida
- Division of Neurological Surgery, Chiba Cancer Center, Chiba, Japan
| | - Naoki Okada
- Department of Pediatrics, Kanazawa Medical University, Kanazawa, Japan
| | - Hiroyoshi Watanabe
- Department of Pediatrics, Graduate School of Medical Sciences, Tokushima University, Tokushima, Japan
| | - Michio Ozeki
- Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan
| | - Yoshiki Arakawa
- Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Junichi Yoshimura
- Department of Neurosurgery, University of Niigata, Brain Research Institute, Niigata, Japan
| | - Yukihiko Fujii
- Department of Neurosurgery, University of Niigata, Brain Research Institute, Niigata, Japan
| | - Souichi Suenobu
- Department of Pediatrics, Faculty of Medicine, Oita University, Oita, Japan.,Division of General Pediatrics and Emergency Medicine, Department of Pediatrics, Oita University, Oita, Japan
| | - Kenji Ihara
- Department of Pediatrics, Faculty of Medicine, Oita University, Oita, Japan
| | - Junichi Hara
- Department of Pediatric Hematology and Oncology, Osaka City General Hospital, Osaka, Japan
| | - Akiyoshi Kakita
- Department of Pathology, University of Niigata, Brain Research Institute, Niigata, Japan
| | - Mari Yoshida
- Department of Neuropathology, Aichi Medical University, Institute for Medical Science of Aging, Aichi, Japan
| | - Yasushi Iwasaki
- Department of Neuropathology, Aichi Medical University, Institute for Medical Science of Aging, Aichi, Japan
| |
Collapse
|